Low‐dose colchicine vs placebo
Serious adverse events · acute gout
1 finding from 1 review
- no estimate extracted1 study · 133 participantsGRADE not reported
Findings
What do systematic reviews say?
112 questions · 112 findings · 9 reviews
No studies found 35 · 31.3%GRADE not reported 21 · 18.8%Very low 13 · 11.6%Low 20 · 17.9%Moderate 23 · 20.5%High 0 · 0%
Low‐dose colchicine vs placebo
Total adverse events · acute gout
Low‐dose colchicine showed no clear difference in total adverse events compared with placebo (low certainty).
1 finding from 1 review
- RR 1.32 [0.68, 2.56]1 study · 103 participantsLow
Low‐dose colchicine vs placebo
Withdrawals due to adverse events · acute gout
1 finding from 1 review
- no estimate extracted1 study · 133 participantsGRADE not reported
High‐dose colchicine vs placebo
Proportion with 50% or greater decrease in inflammation score from baseline ‐ 32 to 36 hours · acute gout
High‐dose colchicine may leads to higher reduction of inflammation: proportion with 50% or greater decrease… compared with placebo (low certainty).
1 finding from 1 review
- RR 10.5 [1.48, 74.38]1 study · 43 participantsLow
High‐dose colchicine vs placebo
Function of target joint ‐ not measured · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
High‐dose colchicine vs placebo
Serious adverse events · acute gout
1 finding from 1 review
- no estimate extracted1 study · 111 participantsGRADE not reported
High‐dose colchicine vs placebo
Total adverse events · acute gout
High‐dose colchicine may leads to higher total adverse events compared with placebo (low certainty).
1 finding from 1 review
- RR 3.21 [2.01, 5.11]2 studies · 124 participantsLow
High‐dose colchicine vs placebo
Withdrawals due to adverse events · acute gout
1 finding from 1 review
- no estimate extracted1 study · 111 participantsGRADE not reported
High‐dose colchicine vs placebo
Pain ‐ not reported · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
High‐dose colchicine vs placebo
Participant global assessment of treatment success: proportion with 50% or greater decrease in pain score from baseline ‐ 32 to 36 hours · acute gout
High‐dose colchicine may leads to higher participant global assessment of treatment success: proportion with… compared with placebo (low certainty).
1 finding from 1 review
- RR 2.16 [1.28, 3.65]2 studies · 124 participantsLow
Colchicine plus standard care vs placebo or usual care
All‐cause mortality assessed up to day 28 · individuals with moderate or severe COVID‐19
1 finding from 1 review
- no estimate extracted2 studies · 11445 participantsModerate
Colchicine plus standard care vs placebo or usual care
Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 · individuals with moderate or severe COVID‐19
1 finding from 1 review
- no estimate extracted2 studies · 10916 participantsModerate
Colchicine plus standard care vs placebo or usual care
Improvement of clinical status: participants discharged alive up to day 28 without clinical deterioration or death · individuals with moderate or severe COVID‐19
1 finding from 1 review
- no estimate extracted1 study · 11340 participantsModerate
Colchicine plus standard care vs placebo or usual care
Quality of life, including fatigue and neurological functioning; · individuals with moderate or severe COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Colchicine plus standard care vs placebo or usual care
Adverse events ( · individuals with moderate or severe COVID‐19
1 finding from 1 review
- no estimate extracted1 study · 72 participantsVery low
Colchicine plus standard care vs placebo or usual care
Serious adverse events ( · individuals with moderate or severe COVID‐19
1 finding from 1 review
- no estimate extracted1 study · 105 participantsVery low
Colchicine (oral) vs placebo
Number of participants experiencing an attacka · people with familial Mediterranean fever
Colchicine (oral) may leads to lower number of participants experiencing an attacka,b compared with placebo (low certainty).
1 finding from 1 review
- Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes onlyRR 0.21 [0.05, 0.95]1 study · 10 participantsLow
Colchicine (oral) vs placebo
Duration of attackse,f · people with familial Mediterranean fever
1 finding from 1 review
- Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 9 participantsVery low
Colchicine (oral) vs placebo
Time between attacks · people with familial Mediterranean fever
1 finding from 1 review
- Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 11 participantsVery low
Colchicine (oral) vs placebo
Prevention of AA amyloidosis · people with familial Mediterranean fever
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for reducing inflammation in familial Mediterranean fever 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found